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Aims: Among diabetes mellitus (DM) patients with poor glycemic control enrolled into a
self-monitoring of blood glucose (SMBG) program in Kenya, to assess the level of SMBG
adherence, its associated factors and its relation to glycemic control (defined as HbA1c <7%
and/or 2% absolute reduction relative to baseline).
Methods: In this retrospective cohort study, we used routinely collected data of patients
enrolled during 2012–2013. We assessed adherence to SMBG by dividing the number of
glucose tests performed by the number recommended. A level of 80% was considered
‘good adherence’. Glycemic control was considered as absolute change from baseline of 2%.
Results: Of 164 patients (59% female; 76% rural), the proportions with good SMBG adherence
were 34%, 17%, 15% and 10% during 0–6, 7–12, 13–18 and 19–24 months into the HGM program
respectively. In multivariate analysis, male gender, urban place of residence and payment for
glucostrips were associated with poor adherence during 0–12 months. The mean reduction in
HbA1c compared to baseline was 1.2%, 1.1%, 0.8% and 0.7% at 6, 12, 18 and 24 months,
respectively. We did not find any association between SMBG adherence and glycemic control.
Conclusions: Adherence to SMBG was sub-optimal, especially among those who had to pay
for glucostrips. Patient education and provision of free glucostrips are recommended to
improve adherence and glycemic control.
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Globally, there were an estimated 387 million people living
with DM (about half of them undiagnosed) and 4.9 million
deaths in 2014 [1]. Nearly half of all DM deaths occurred in
people aged less than 60 years globally, reaching 75% in less
developed regions of sub-Saharan Africa. The number of DM
patients is projected to increase to an astounding 592 million
by 2035 [1]. In Kenya, the rising burden of DM remains largely
neglected as the country is still struggling with infectious
diseases. It is estimated that in 2014 775,210 DM cases were
recorded in Kenya with 582,000 people with DM remaining
undiagnosed [1]. Most of these patients present late and may
not get the standard of care they need, leading to high
morbidity and mortality.
A key component of DM management is self-monitoring of
blood glucose (SMBG), which is proven to improve glycemic
outcomes in patients with DM [2–4]. SMBG is tailored to meet
the needs of the patient and varies depending on the
treatment the patient is on [5]. Like in other interventions,
patient adherence remains key to achieving good outcomes
[6]. Adherence is defined by the World Health Organization as
the extent to which a person’s behavior – taking medication,
following a diet and/or executing lifestyle changes – corre-
sponds with agreed recommendations from a health care
provider [7]. Adherence to SMBG therefore requires that
patients test their blood sugar as advised by the healthcare
provider, in terms of frequency and timing. The overall
evidence about adherence to SMBG among DM patients is
limited and most of the evidence comes from the United States
of America, Europe or Asia [2,3,8,9]. We could not identify any
published evidence on this issue from Africa.
At the Moi Teaching and Referral Hospital (MTRH) in Kenya,
patients with DM who meet a certain criteria (Section 2.3) are
enrolled into a home-based SMBG program, educated and
provided with an electronic blood glucose meter to conduct
intensive SMBG. Patients are contacted via telephone once a
week and are expected to give the SMBG readings for that week.
The SMBG readings are then used to guide a healthcare provider
in adjusting their medication. However, it has been observed in
the program that the glycemic control of some of the patients
remains lower than expected and it is not clear whether this is
related to patient’s adherence to SMBG. Therefore we aimed to
assess the adherence to SMBG in this group and its relation to
glycemic control. The specific objectives were to (1) determine
the adherence to SMBG at different time points into the
program, (2) identify the demographic and clinical character-
istics associated with non-adherence to SMBG and (3) assess
whether adherence to SMBG is associated with glycemic control
and hospital admissions and emergency room visits.
2. Methods
2.1. Study design
This is a retrospective cohort study using the routinely
collected data of DM patients enrolled into the home based
care program.2.2. General setting
Kenya is located in East Africa with a population of 43.2 million
as of 2012. The country is divided into 47 administrative
counties. The health care delivery system in Kenya is divided
into six levels. Level 6 represents the national referral
hospitals which are currently two in the country, level 5
represents county referral hospitals, level 4 represents sub
county referral hospitals and levels 3–1 represent the primary
health care facilities. Currently DM management is mostly
confined to level 4, 5 and 6 hospitals where comprehensive DM
management teams and services are likely to be found. The
current DM prevalence in the country is estimated at 3.6% [1]
which may be an under representation due to lack of data
collection tools to report on DM cases in the country as well as
the fact that most DM patients remain undiagnosed.
The Moi Teaching and Referral Hospital, located in Eldoret
town (310 km Northwest of Nairobi, the capital city of Kenya),
is the second largest referral hospital in the country. The
hospital serves a catchment population of 16.4 million people
[10]. The hospital runs DM outpatient clinics and currently has
about 3000 patients on care. The main occupation in the
catchment population is farming with most people engaging
in subsistence farming.
The Academic Model providing Access to Health Care
(AMPATH) is a collaboration between Moi University College
of Health Sciences (MUCHS), Moi Teaching and Referral Hospital
(MTRH) and a consortium of North American academic medical
centers led by Indiana University. AMPATH was first established
as a response to the HIV pandemic but in collaboration with
Ministry of health (MOH) has diversified to other chronic
illnesses [11]. The chronic disease management (CDM) program
of AMPATH oversees management of DM patients including
those in the SMGB program in western Kenya.
2.3. Home glucose monitoring (HGM) SMBG program
As part of chronic disease management program, patients are
enrolled into a home glucose monitoring program based on
strict pre-defined criteria that includes all children, adoles-
cents and adults with poor glycemic control. The program has
two distinct arms. Arm 1 constitutes all children, adolescents
and adults with very poorly controlled DM as assessed by an
HbA1c above 13% and/or established DM complications. Arm 2
constitutes financially able adults who are mainly on Oral
Glucose Lowering Agents (OGLAS) or on insulin. These
patients are also poorly controlled but have HbA1c below
13% and meet a certain criteria for SMBG such as hypoglyce-
mic episodes or an established DM complication. The patients
in arm 1 receive free glucometers and glucostrips while those
in Arm 2 receive a free glucometer but pay a subsidized fee of
Kshs 500 ($5.90) which is much lower than the market price of
Kshs 3000 ($37.50) for a box of 50 glucostrips. All the patients
receive free DM diaries and have access to all the HGM services
irrespective of the arm assigned.
Once enrolled, the patients are trained by a DM educator on
SMBG, use of the DM diary and their medication. The diabetes
clinic currently has one diabetes educator who serves all the
clients. As a result of this, most patients receive one session of
diabetes education which in most cases is individualized
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 1 2 ( 2 0 1 6 ) 3 7 – 4 3 39without involving other family members. The issued gluc-
ometers are pre-programmed to keep records for up to a
month to allow for validation of results. Patients are required
to test their blood sugar as advised by the clinician and record
it in the diabetes diaries provided to them. The testing
schedule mostly depends on the type of medication the
patient is on. Patients on oral glucose lowering agents (OGLAs)
are expected to test their blood glucose at least 3 days per
week, twice a day (pre-breakfast and/or pre-dinner or 2 h post
meal). Patients on twice daily insulin injection are expected to
test daily at least twice a day (pre-breakfast and pre-dinner)
while those on basal bolus injections of insulin are required to
test daily at least three times a day (pre-breakfast and pre-
dinner and post-meal at any time).
The patients are contacted via telephone by HGM staff each
week to enquire about the blood glucose readings of the
previous week and their general well-being. During the call,
patients are expected to read the blood glucose readings noted
in their diaries. The readings are then entered into a database
with each patient having a unique database number. On a
weekly basis, a clinician reviews these readings and advises the
adjustments to the doses of medication, if required. The
patients are then called back and informed about the new
insulin doses. Patients on oral medication are required to visit
the hospital, in case it is warranted to change the medication
based on physician’s advice. Patients also get a HbA1c test every
three months for those in Arm 1 and every six months for those
in Arm 2 as they pay for it and may not afford to do it every 3
months. Patients are required to adhere to their normal clinic
dates, and on these visits they bring in their diabetes diaries and
glucometers which are used to validate the self-reported
readings collected over telephone. A hospital-based patient file
is maintained which contains information on their clinic visits,
admissions, visits to the emergency room and laboratory
results. All the services under the program are provided free
of charge to the patients with the exceptions mentioned above.
2.4. Study population
All patients enrolled into the HGM between January 2012 and
December 2013, and who were in the program for at least six
months were included in the study.
2.5. Data variables and data extraction
Data variables included: age, gender, place of residence, type
of medication, presence of co-morbidity such as Hypertension
or any associated DM complication, duration of DM, payment
for glucostrips, actual number of blood sugar tests done,
expected number of blood sugar tests, HbA1c and hospital
admissions and emergency visits. Data were retrieved from
the HGM data base and patient record files. Data on SMBG,
HbA1c and hospital admissions and emergency visits were
censored on 30th June 2014.
2.6. Operational definition of adherence and glycemic
control
Adherence to SMBG was calculated by dividing the actual
number of SMBG readings received from the patient by theexpected number of SMBG readings at 6, 12, 18 and 24 months.
Adherence level of 80% or more was considered good
adherence, and lower than this was regarded as poor
adherence. We defined glycemic control as HbA1c <7% or
an absolute reduction of 2% in HbA1c value from the baseline.
2.7. Data entry and analysis
Data was single entered and analyzed using EpiData software
(version 3.1 for data entry and version 2.2.2.182 for analysis,
EpiData association, Odense, Denmark). Adherence to SMBG
at different time periods (months 0–6, 7–12, 13–18 and 19–24)
was expressed as proportions. For the purpose of assessing
factors associated with poor adherence, we restricted our
analysis by calculating adherence for 0-12 months as the
patients with follow up data for more than 12 months were
few.
To assess possible association of demographic and other
characteristics with poor adherence to SMBG, we calculated
relative risks (RR) with 95% confidence intervals (CI). Those
variables which were significant at p-value of less than 0.1
were included in a multivariate model. Adjusted relative risks
were calculated using Poisson regression model with a robust
variance estimator to assess the independent effect of factors
on poor adherence to SMBG. We used STATA (version 12.1, TX,
USA) for the multivariate analysis. p-Value of less than 0.05
was considered statistically significant for all analyses.
2.8. Ethics
Permission to carry out the study was obtained from MTRH.
Ethics approval was obtained from the Institutional research
and ethics committee (IREC) at MTRH and the Ethics Advisory
Group of the International Union against Tuberculosis and
Lung Disease, Paris, France. As this study was done using
routinely maintained records, the need for individual in-
formed consent from the patients was waived by the ethics
committees.
3. Results
A total of 164 DM patients were included in the study. The
median (interquartile range) age of the participants was 33
(21–55) years, 59% were female and 76% were from rural areas.
The demographic and clinical characteristics of study parti-
cipants are summarized in Table 1. Most of the patients were
receiving insulin with 69.5% being on pre mixed insulin (70/30)
and 4.3% on a basal bolus insulin regimen. The mean duration
of DM since diagnosis was 5 years. About one-fourth of the
patients had to pay for the glucostrips.
Adherence to SMBG at different time periods is described in
the Fig. 1. At 0–6 months into the HGM program, 34% had good
adherence to SMBG. The proportion with good adherence
further decreased to 17%, 15% and 10% during 7–12 months,
13–18 months and 19–24 months, respectively.
Of all the 164 patients, there were 121 who had follow up
data up to 12 months. Between 0 and 12 months, the
proportion of patients with poor adherence was 78%. Factors
associated with poor adherence during 0–12 months are
Table 1 – Demographic and clinical characteristics of DM
patients enrolled into the home glucose monitoring
program at MTRH, Eldoret Kenya, 2012–2013.
Characteristics Number (%)
Total 164 (100)
Age groups
<15 years 8 (4.9)
15–24 years 51 (31.1)
25–34 years 27 (16.5)
35–44 17 (10.4)
45–54 15 (9.1)
55–64 31 (18.9)
65 15 (9.1)
Gender
Male 68 (41.5)
Female 96 (58.5)
Place of residence
Rural 125 (76.2)
Urban 39 (23.8)
Type of DMa medication
Only oral medication 11 (6.7)
Insulin alone/Insulin + oral medication 153 (93.3)
Co morbid condition
Present 38 (23.2)
Absent 126 (76.8)
Payment for glucostrips
Paying 34 (20.7)
Not paying 130 (79.3)
Duration of DM
0–2 years 43 (26.2)
3–5 years 38 (23.2)
>5 years 79 (48.2)
Not recorded 4 (2.4)
a DM-Diabetes mellitus.
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years, male gender, urban place of residence and payment for
glucostrips were associated with poor adherence. In multivar-
iate analysis, male gender, urban place of residence and34
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Fig. 1 – Adherence to self-monitoring of blood glucose and
glycemic control among DM patients at different time
periods after enrollment into self-monitoring program,
Kenya, 2012–2013.payment for glucostrips were identified as risk factors for poor
adherence.
The trend in mean HbA1c is shown in Fig. 2. Improvement
in glycemic control was highest in the first 6 months and
decreased in subsequent months. The mean reduction in
HbA1c compared to baseline was 1.2% (95% CI, 0.8–1.7), 1.1%
(95% CI, 0.5–1.7), 0.8% (95% CI, 0.1–1.7) and 0.7% (95% CI, 0.7 to
2.0) at 6, 12, 18 and 24 months, respectively. At 12 months of
follow up, 33% of patients achieved glycemic control.
There was no association between adherence to SMBG and
glycemic control at 12 months among those adherent
(accounting for 38%) and among the non-adherent (accounting
for 40%; RR = 1.0, 95% CI 0.7–1.4, p = 0.84).
Of 121 patients who had a minimum follow up time of 12
months, 46 (38%) patients had at least one unscheduled visit
(hospital admission or emergency room visit) to hospital
related to DM. Poor adherence was not associated with
unscheduled visits (RR = 1.23, 95% CI 0.69, 2.22, p = 0.5).
4. Discussion
Our study among DM individuals with poor glycemic control at
enrollment in a home glucose monitoring program showed
that adherence to SMBG was not optimal. More than 75% of DM
patients were poorly adherent during 0–12 months after
enrollment and this increased to 90% after 18 months. Being
male, residing in urban area and paying for glucostrips were
associated with poor adherence to SMBG. The mean HbA1c
kept fluctuating through the program—reduced from baseline
in the first 6 months then increased at 12 months, followed by
a decline in the 18th month and a rise again in the 24th month.
Despite this trend, the reduction in HbA1c from baseline was
maintained and did not worsen to baseline level or more.
Though there was reduction in HbA1c levels from the baseline
after enrollment, adherence to SMBG was not associated with
glycemic control.
Our study findings of poor adherence to SMBG confirm the
results of previous studies on adherence from US, Europe and
Asia [6,8]. A study done in Central Texas [4] using 80% cut off
for defining adherence reported that only one third of DM
patients were adherent to SMBG which was higher than the
present study. However this study may not be comparable to
other studies in developed countries as adherence is influ-
enced by many factors like literacy level of patients, family
support, presence of disease complications and support
systems like provision of diabetes educator and reminders.
All the above factors may be completely different in this study
setting from the rest of the previous studies from developed
and developing countries. Unlike the previous studies, only
DM patients with poor glycemic control were enrolled in the
present study and hence the level of adherence and glycemic
control achieved is expected to be different.
Payment for glucostrips was associated with poor adher-
ence in the present study. Though glucostrips were provided
at subsidized cost, still for many patients this cost may be
unaffordable due to other associated costs of DM manage-
ment. The study from Central Texas reported similar findings
that fewer environmental barriers including costs were
significantly associated with good adherence. Another factor
Table 2 – Factors associated with poor adherence to self-monitoring of blood glucose among DM patients at 12 months
after enrollment into the home glucose monitoring program at MTRH, Eldoret Kenya, 2012–2013 (N = 121).
Variables Total Poor adherence N (%) RR (95% CI) Adjusted RR (95%CI)
Age groups
0–29 years 59 40 (68) Ref
30 years 62 54 (87) 1.3 (1.1,1.6) 1.1 (0.9, 1.4)
Sex
Male 50 41 (82) 1.1 (0.9,1.3) 1.1 (1.1, 1.1)
Female 71 53 (75) Ref
Area of residence
Urban 31 27 (87) 1.2 (1.0,1.4) 1.1 (1.1,1.1)
Rural 90 67 (74) Ref
Comorbidity
Present 25 21 (84) 1.1 (0.9,1.4)
Absent 96 73 (76) Ref
Duration of DM
0–2 years 32 24 (75) Ref
3–5 years 31 21 (68) 0.9 (0.7,1.3)
>5 years 56 47 (84) 1.1 (0.9,1.4)
Medication type
Insulin 114 88 (77) 0.9 (0.7,1.2)
Oral medication 7 6 (86) Ref
Payment for glucostrips
Paying 23 22 (96) 1.3 (1.1, 1.5) 1.3 (1.1,1.5)
Non paying 98 72 (74) Ref
RR—relative risk, CI—confidence interval.
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finding was reported by the study from China, where females
were more adherent to SMBG. Exact reasons for this difference
are not known and role of behavioral characteristics can be
explored by future qualitative studies.
Our study did not find any association between adherence
to SMBG and glycemic control and this could be related to
small sample size. The patients enrolled in the program are
enrolled on criteria of being poorly controlled and this may
have biased the assessment of glycemic control. These
patients could also represent a pool of generally non adherent
patients given the poor control present at enrollment which
may also affect the level of adherence to SMBG observed.
There are also other factors that could impact glycemic control9
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Fig. 2 – Trend in mean HbA1c level among DM patients at
different time periods after enrollment into self-
monitoring program, Kenya, 2012–2013.other than adherence to SMBG which were not assessed in our
paper such as medication adherence, adherence to lifestyle
modification, type of medication and peer and family support.
However there was overall reduction in HbA1c levels in the
first six months after enrollment into the program and this
reduction was sustained thereafter. This is similar to findings
in other studies where intensive SMBG was associated with
improvements in HbA1c [2,8]. The trend in mean HbA1c
observed is suggesting a pattern where patients improve their
glycemic control which is followed by a period of poor DM
practices possibly influenced by the apparent improvement.
This is later followed by a period of good DM practices with
resultant decline in HbA1c possibly due to panic induced by
the worsened control. Many studies have reported the positive
association between adherence and glycemic control [2]. The
design of the program may not also facilitate attainment of
glycemic control. This is due to the testing being done twice
only which may not allow for adequate insulin dose adjust-
ments. The type of insulin being used may have an implication
on the level of glycemic control achieved. Majority of the
patients are on premixed insulin due to its easy availability
and low. This makes adjustment of insulin doses to cater for
post meal hyperglycemia which compromises the level of
glycemic control achievable.
The study findings have several implications. First,
considering the overall low level of adherence to SMBG,
routine counseling/DM education for this group needs to be
improved. Structured educational materials on DM and SMBG
targeting high risk groups like urban males can be developed
and implemented. There is also a need to invest more in DM
educators to facilitate provision of this essential service to the
patients. Adherence to SMBG should be assessed at every
hospital visit and the reasons for poor adherence should be
sought. Diabetes educators and other health care providers
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SMBG and their counseling to DM patients should include
sections on overcoming poor adherence to SMBG.
Second, provision of glucostrips at lower fees to patients in
developing countries should be considered to facilitate SMBG
in these patients. Third, considering the poor glycemic control
at enrollment into the program, this select group of patients
needs more comprehensive interventions (including advice
for dietary changes and exercise) to improve glycemic control
in addition to SMBG. The trend in mean HbA1c indicates that
SMBG needs to be continuous to capture these trends and
patient education needs to be sustained even when glycemic
control is improving to avoid relapses to poor glycemic control.
There should also effort to avail, at more affordable costs,
basal bolus insulin regimens to DM patients in developing
countries to allow control of post meal hyperglycemia which is
the greatest contributor to glycemic control [12].
Future studies, if possible prospective, multicenter studies
need to be planned with larger sample size, to assess other
factors affecting SMBG and glycemic control. Qualitative
studies are also recommended to understand the barriers to
SMBG from patients’ perspective.
Our study has several strengths. To the best of our
knowledge, this is the first study from Africa on adherence
to SMBG and its impact on glycemic control. Second,
information on number of SMBG readings were validated
with glucometer readings reducing the recall bias during self-
reporting. Third, we used the HbA1c values for assessing
glycemic control which is a robust measure. There were also a
few limitations. We did not study environmental factors
associated with adherence like family support, inconvenience
and pain due to self-testing. This study was conducted at one
referral hospital and generalizability of the study findings to
other hospitals or other African countries may be limited.
Finally, post hoc power calculation showed that we were
grossly underpowered to detect association between SMBG
adherence and glycemic control.
5. Conclusion
Adherence to SMBG was sub-optimal among DM patients
enrolled in a home based glucose monitoring program and
decreased with increase in duration of follow-up. Glycemic
control was best at initial follow up and declined subsequently
but never reverted to baseline. Patient and health provider
education including provision of affordable glucostrips to all
patients are needed to improve adherence. There is need to
invest in more SMBG programs in developing countries to allow
the improved monitoring and management of DM patients.
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